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The activity of hepatitis varies in chronic hepatitis C virus (HCV) infection. Some patients show persistently normal serum
alanine aminotransferase (ALT) values, whereas the others show high-ALT values and progress to liver cirrhosis or
hepatocellular carcinoma. However, virological mechanisms causing hepatitis have not fully been elucidated. We analyzed
serial changes in full-length HCV sequences in 10 patients with various profiles of hepatitis activity. In the nonstructural 5A
(NS5A) and NS5B, the rate of amino acid changes, as well as the proportion of nonsilent ones, was low in patients with normal
ALT values compared with those with abnormal ALT (for the rate of amino acid changes, 0 3 1023 vs 3.19 3 1023
changes/site/year (P 5 0.037) in NS5A and 0 3 1023 vs 1.22 3 1023 changes/site/year (P 5 0.023) for NS5B, for the
proportion of nonsilent changes, 4 vs 22% (P 5 0.017) in NS5A and 0 vs 16% (P 5 0.039) in NS5B). Also, the flare-up of
hepatitis coincided with higher nucleotide/amino acid substitution rates in NS5B. In conclusion, the genomic structures of the
NS5A and NS5B regions may correlate with hepatitis activity in chronic hepatitis C. © 1999 Academic Press
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Hepatitis C virus (HCV) is a single-strand RNA virus
hat consists of ;9500 nucleotides (Choo et al., 1989;
anaka et al., 1996; Major and Feinstone, 1997). Persis-
ent HCV infection causes chronic hepatitis C and devel-
ps liver cirrhosis (LC) and hepatocellular carcinoma
HCC) over the course of 20–30 years in a vast majority
f patients (Kiyosawa et al., 1990). On the other hand, the
xistence of “asymptomatic HCV carrier” also has been
eported, who shows persistently normal serum alanine
minotransferase (ALT) values and minimal changes in
iver histology (Prieto et al., 1995). A better long-term
rognosis is suggested in those patients. Furthermore
epatitis activity is variable even in a single patient, and
erum ALT values may fluctuate and show a low-ALT
alue phase followed by a high-ALT phase and vice
ersa. Therefore it is of clinical and virological impor-
ance to clarify the mechanism of liver damage induced
y chronic HCV infection.
So far, both the direct cytopathic mechanism of HCV
Alberti et al., 1992) and the host’s immune-mediated
echanism (Nelson et al., 1997) have been proposed in
he pathogenesis of hepatitis in chronic hepatitis C.
The 20 full-length HCV sequence data are registered to GenBank as
ccession Nos. AF165045–AF165064.
1 To whom reprint requests should be addressed. Fax: 81-3-5803-
s152. E-mail: c.sato.ns@med.tmd.ac.jp.
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244owever, the precise mechanism has not fully been
lucidated. From a virological point of view, quasispecies
iversities of the hypervariable region 1 (HVR-1) (Kuro-
aki et al., 1994; Koizumi et al., 1995; Naito et al., 1995,
uki et al., 1997) and the core region (Kurosaki et al.,
995; Hayashi et al., 1997) were assessed, and the rela-
ionship between genomic complexity of HCV and hep-
titis activity or disease progression was suggested in
hose studies. However, the relationship between hepa-
itis activity and whole HCV genomic structures has not
een assessed. In the present preliminary study, we
ompared full-length HCV sequences longitudinally in 10
atients who showed different patterns of serum ALT
hanges during their clinical course to identify HCV
enomic regions associated with hepatitis activity.
RESULTS
In all 10 patients, the detected full-length HCV se-
uence changed during the observation period. HCV
enomes from all patients except Patient 6 consisted of
401 nucleotides plus the X-tail of 98 nucleotides, and
here was an open reading frame of 3010 amino acids
ith similar genomic organizations to those of HCV-J. In
atient 6, there was a 9-bp insertion at the 59 terminus of
VR-1.
Nucleotide changes were observed throughout the
enome except 39NCR that was completely stable. The
equence of the X-tail was also conserved, although the
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245HCV FULL-LENGTH SEQUENCES AND HEPATITIS ACTIVITYomparison could be made in only six patients due to
nsuccessful PCR amplification. The sequence of 59NCR
as also highly stable, and a total of three nucleotide
hanges were observed in only two patients: two in
ositions that coded the single-stranded region or the
oop structure [nt 300 (T to A), 328 (C to T) in Patient 9]
nd one in the stem [nt 92 (T to C) in Patient 1] (Smith et
l., 1995).
As shown in Table 1, the changes in amino acid resi-
ues were distributed over almost all regions of the HCV
enome, and there were no specific residues that
hanged commonly in the multiple patients. In this anal-
sis, there were no residues difficult to judge whether
hey changed or not because of the comparable height of
he electrophoregram peaks. Amino acid residues that
re previously reported as functionally important were
ighly conserved. The cleavage site for each polyprotein
oding region (Major and Feinstone, 1997), aa 952 and
93 of the NS2 protein that is essential for the NS3-
ependent cleavage between NS2–NS3 (Grakoui et al.,
993), aa 489–491 of the E2 protein that is indispensable
or the formation of the E1-E2 heterodimer (Yi et al.,
997), and transmembrane domain of E2, were not af-
ected (Cocquerel et al., 1998). The catalytic triad of NS3
1083, 1107, 1165) (Miller and Purcell, 1990), 14 amino
cid residues of NS4A (aa 1678–1691) that are essential
or acting as a cofactor of NS3 (Shimizu et al., 1996), and
ssential regions for the RNA-dependent RNA polymer-
se activity of NS5B (GDD motif; aa 2736–2738) (Choo et
l., 1989) were not affected. The interferon sensitivity
etermining region (ISDR) in NS5A (Enomoto et al., 1995)
lso was conserved except for three amino acid changes
hat occurred in Patient 9 in the high-ALT group. In
ccordance with previous reports, a cluster of changes
as observed in the HVR-1 in the N terminus of E2, but
here were no common amino acid changes. However,
urther analysis of the changes in HVR-1 was not per-
ormed because of the methodological limitation inher-
nt in direct sequencing.
The difference of sampling intervals among the pa-
ients was corrected by a division by year. The overall
ubstitution rate of nucleotides and amino acids in the
ull-length HCV genome was not different between the
wo group [for nucleotide: 3.33 (1.83–6.41) vs 4.17 (2.25–
2.0) 3 1023 changes/site/year (P 5 0.831), for amino
cid: 1.23 (1.0–3.70) vs 2.58 (1.64–6.67) 3 1023 changes/
ite/year (P 5 0.136)]. When the comparison was made
eparately in each polyprotein coding region, the normal
LT group had lower substitution rates of amino acids in
S5A and NS5B than the abnormal ALT group [NS5A: 0
0–1.21) vs 3.19 (0–14.3) 3 1023 changes/site/year, P 5
.037, NS5B: 0 (0–2.43) vs 1.22 (0–10.8) 3 1023 changes/
ite/year, P 5 0.023) (Fig. 1)]. In contrast, there were no
ifferences in the nucleotide substitution rate of theseegions [NS5A: 2.56 (0.56–4.98) vs 5.18 (2.11–15.6) 3 1023 nhanges/site/year, P 5 0.201, NS5B: 2.22 (0.68–4.89) vs
.49 (1.07–12.4) 3 1023 changes/site/year, P 5 0.286].
ucleotide and amino acid substitution rates in the other
egions of the HCV genome were not different.
Among six patients in the abnormal ALT group, the
omparison between the flare-up (Patients 5–7) and the
igh-ALT (Patients 8–10) subgroups revealed that substi-
ution rates of amino acids were significantly high in
he flare-up group in NS5B (2.79 vs 0.61 was 3 1023
hanges/site/year, P 5 0.0495; Fig. 1), as well as those of
ucleotides (4.58 vs 3.26 3 1023 changes/site/year, P 5
.0495).
The ratio of non-silent to total mutations in the NS5A
nd NS5B was significantly low in the low-ALT group
ompared with the high-ALT group (NS5A: 4% vs 22%,
5 0.017, NS5B: 0% vs 16%, P 5 0.039), suggesting a
reference for silent mutations in the normal ALT group.
uch a difference was not observed in the other regions
f HCV (Table 2).
DISCUSSION
In the present preliminary study, we analyzed longitu-
inal changes in the full-length HCV genomes from 10
atients in relation to the activity of hepatitis. Although
here are two reports that describe longitudinal changes
n the full-length HCV genome: one in a chronic hepatitis
atient (Ogata et al., 1991) and the other in a chimpanzee
Okamoto et al., 1992a), the detail of clinical courses is
ot shown. Therefore the present study is the first report
n longitudinal changes in the full-length HCV genome
onsidering clinical courses of multiple patients. Further-
ore the virological mechanism of asymptomatic HCV
arrier has not been fully elucidated (Naito et al., 1994;
hindo et al., 1995). Previous studies analyzed only lim-
ted regions of the HCV genome, such as the HVR-1
Kanto et al., 1994) or the core region (Hayashi et al.,
997). Therefore we attempted to clarify sequence(s)
esponsible for the hepatitis activity. As a result, the rate
f amino acid changes in NS5A/B was significantly low
n patients with normal ALT levels, as well as the pref-
rence for silent mutations. A linkage between the hep-
titis activity and the low substitution rate was sug-
ested, although causal relationship of these two events
s still not clarified. Additionally, in both nucleotide and
mino acid levels, the substitution rate of NS5B was
ignificantly high in patients with flare up of hepatitis
ompared to those with persistently high hepatitis activ-
ties.
In this study, only the dominant sequences were ana-
yzed by direct sequencing. Although the possibility that
inor populations also contribute to the pathogenesis of
epatitis cannot be fully excluded, we believe it reason-
ble to postulate the dominant clone (or HCV of domi-
ant sequence) determine the major part of disease
CE
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E
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246 NAGAYAMA ET AL.TABLE 1
Changed Amino Acid Residues during the Observation Period
Region (codon)
Low ALT group
Abnormal ALT groups
Flare-up group High ALT group
1a 2 3 4 5 6 7 8 9 10
ore (1–191)
10 K3R
68 V3A
91 M3L
121 R3K
1 (192–383)
217 A3V
219 V3I
227 T3M
233 G3D
244 P3S
253 I3V
255 I3T
291 L3F
VR-1 (384–410)
384 N3E H3Y
385 S3T
386 Y3H
388 S3T T3S
391 V3A T3A A3T
393 G3S
394 R3H K3Q H3R H3R
395 L3I Q3H
396 T3A
397 H3R L3H S3Y S3F
398 G3A G3R S3R T3I
399 I3V L3F
400 T3A V3A M3T
401 G3S
402 M3L F3L
403 F3L
405 V3F P3S F3V
410 R3K K‘3N
2 (411–473)
434 H3Q
449 S3A
457 D3A
464 R3G
471 S3P
VR-2 (474–480)
475 V3A T3A
477 P3H G3R
479 S3N
2 (481–809)
514 I3V
528 S3R
531 A3E
568 L3P
580 T3I
608 I3L
641 T3N
EN
N
N
N
N
N
247HCV FULL-LENGTH SEQUENCES AND HEPATITIS ACTIVITYTABLE 1—Continued
Region (codon)
Low ALT group
Abnormal ALT groups
Flare-up group High ALT group
1* 2 3 4 5 6 7 8 9 10
2 (481–809)
712 I3F
723 F3L
779 K3Q
805 P3S
S2 (810–1026)
846 L3F M3L
941 L3V
951 N3D
957 R3Q
975 V3I
978 D3E
1017 S3N
1018 L3I
S3 (1027–1657)
1033 S3A
1044 V3 I
1082 Y3F
1176 A3 V
1355 I3V
1576 N3T
1608 W3L
S4A (1658–1711)
1694 I3V
1703 Q3R
S4B (1712–1972)
1747 V3A
1835 T3A
1950 S3N
S5A (1973–2420)
1989 T3S
2050 K3R
2080 R3K
2098 D3E
2110 V3I
2155 P3T
S5A (1973–2420)
2171 L3P
2185 A3T
2216 T3P
2218 H3N
2223 D3G
2261 A3V
2303 A3D
2305 D3G
2339 S3T
2349 T3V
2355 P3S
2411 Q3E
2412 D3G
2416 V3L
2417 V3I
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248 NAGAYAMA ET AL.henotype. Alternatively, the dominant clone is the most
it in the hepatic environment at a particular time, be-
ause it is under the least attack by the immune system.
Furthermore quasispecies analysis of full-length HCV
enomes from clinical samples is not practical at the
resent time. Additionally, due to the possible bias in
ested PCR, it is possible that some minor sequences
ere selectively enriched. However, it may occur in the
TABLE
Region (codon)
Low ALT group
1* 2 3
S5B (2421–3010)
2491
2498
2617
2625
2632
2650
2719
2729
2754
2920
2924
2963
2968
2975
Note. Amino acids are denoted by single letter codes. Codons are n
a Patient number.FIG. 1. The rate of amino acid substitutionsame manner in each experiment and may be canceled
t the comparison of the sequences.
There were no significant differences in nucleotide or
mino acid substitution rates in the other regions. In a
revious study, the quasispecies diversity of the core
egion was analyzed (Hayashi et al., 1997). Although the
iversity of nucleotide sequences was similar between
atients with persistently abnormal and normal ALT lev-
tinued
Abnormal ALT groups
Flare-up group High ALT group
5 6 7 8 9 10
N3K
N3K
G3K
K3N
S3N
N3S
T3S
D3N
N3S
I3R
K3R
R3Q
S3G
S3G
ed according to HCV-J.1—Con
4
umberin each polyprotein coding region.
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249HCV FULL-LENGTH SEQUENCES AND HEPATITIS ACTIVITYls, patients with abnormal ALT values tended to have a
igher rate of nonsilent mutations. As a result, amino
cid sequences in the core region were more divergent
n patients with abnormal ALT levels. These cross-sec-
ional findings suggest that the occurrence of nonsilent
utations in the core region may be a determinant of
iver damage. In the present study, however, there were
o differences in the longitudinal substitution rates of
ucleotides or amino acids in the core region. Further-
ore, the proportion of nonsilent mutations was similar
etween them (13% vs 9%).
The relationship between the changed amino acids
nd the function of NS5B is largely unknown. Because
S5B is identified as a region coding an RNA-dependent
NA polymerase (RdRP) (Behrens et al., 1996) and is the
ajor replicase component of HCV, mutations in this
egion may affect the replication efficiency of HCV. The
ssential amino acid residues for the RdRP activity of
S5B include the GDD motif (aa 2736–2738) (Choo et al.,
989), several amino acids (aa 2639, 2644, 2702, 2706,
710) (Lohmann et al., 1997), and the carboxyl-terminal
embrane-spanning domain (aa 2990–3010) (Yamashita
t al., 1998). In this study, however, these critical amino
cid residues were not changed, and there were no
ignificant changes in serum HCV–RNA levels during the
bservation period as well. Although amino acid substi-
utions were observed in five of six patients with abnor-
al ALT levels (Table 3), there were no specific amino
cid residues that changed commonly. Additionally, the
lare-up of hepatitis activity coincided with higher muta-
ion rates in NS5B. Although virological mechanisms
nderlying this phenomenon is not clear and major
hanges in the viral load were not observed, this phe-
omenon may involve some alterations of viral replica-
ion mechanism.
The NS5A region also is suggested to be involved in
he replicase complex by comparison with other viruses.
e have previously identified the ISDR (aa 2209–2248) in
S5A that is correlated with the response to IFN therapy
Enomoto et al., 1995). Mutations in this region were
ssociated with favorable outcome of IFN therapy as
ell as low serum levels of HCV. These clinical studies
ndicate that NS5A may be involved in the replication of
CV or may functionally contribute to IFN resistance.
asic studies also suggest the possible role of NS5A in
he pathogenesis of hepatitis C. Recent studies revealed
hat an upstream region of ISDR (aa 2197–2204) contains
yperphosphorylation sites (Tanji et al., 1995), that the
S5A protein binds and represses the dsRNA-depen-
ent protein kinase (PKR) (Gale et al., 1997), and that the
terminus of NS5A (aa 2135–2331) has a transcription
ctivation function (Kato et al., 1997; Fukuma et al., 1998).
lthough changed residues were not involved in these
tudies, further virological research may correlate theseresidues with the pathogenesis of hepatitis.Lo Ab P on
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250 NAGAYAMA ET AL.Major histocompatibility complex (MHC) class I-re-
tricted cytotoxic T lymphocytes (CTL) recognize
pitopes on various regions of HCV (Koziel, 1997). Be-
ause hepatitis is associated with the destruction of
epatocytes by the host immune system including CTL
ttack, the intensity of CTL attack may influence substi-
ution rates in CTL epitopes. For example, an association
etween frequent mutations and active liver disease is
eported in the core region of HBV (Asahina et al., 1996).
here were no amino acid changes in known HLA-
estricted epitopes in a patient whose HLA haplotypes
ould be determined [Patient 5: HLA-A24(9), A26(10),
48, B52(5), Cw8] in this study. However, further studies
ith a larger number of patients are necessary on this
oint.
Recently, Sullivan et al. (1998) reported that quasispe-
ies populations of various genomic regions of HCV
hanged before and after liver transplantation. Their
nalysis focused on the relation between quasispecies
opulation and the pattern of hepatitis activity and found
hat quasispecies diversification was tended to be lower
n low-ALT patients. Although direct comparison be-
ween their results and ours is difficult because the
ohort of their study was under immunosuppressive ther-
py and “host” was different before and after transplan-
ation, both studies suggest the association between
CV sequences and hepatitis activity.
In conclusion, an association between sustained low-
LT values and lower amino acid substitution rates in
S5A and NS5B was observed by the analysis of longi-
udinal changes in the full-length HCV genome. Further-
T
Clinical Backgro
Low ALT group
Patient 1 Patient 2 Patient 3 Pati
ge (yr) 51 36 39 5
ex (M/F) F M F
ampling interval (days) 911 484 673 49
LT at entry (IU/l) 37 15 9 1
LT at flare-up (IU/l) — — — —
latelet count (3104/mm3) 30.8 16.8 20.7 2
CV–RNA (Meq/ml)a
At first sampling point ,0.5 5.0 12 1
At second sampling point ,0.5 4.0 11
istological findingsb
Activity 1 NAc NA N
Fibrosis 0 NA NA N
a HCV-RNA levels were determined by a branched-chain DNA assay
b Histological findings were classified according to the criteria desc
c NA, not available.ore the flare-up of hepatitis activity coincided with wigher substitution rates in NS5B. A possible correlation
s suggested between these sequences and the activity
f chronic hepatitis C.
PATIENTS AND METHODS
atients
Ten patients with chronic HCV infection were studied.
ll patients showed positive serum HCV antibodies
third-generation assay) and HCV–RNA of the genotype
b (Okamoto et al., 1992b; Simmonds et al., 1994). They
ere negative for serum hepatitis B s antigen, anti-HBc
ntibodies, and antinuclear antibodies and had no other
auses of hepatitis including excessive alcohol intake or
epatotoxic drugs. No patients received interferon ther-
py within 6 months before the entry and during the
bservation period. Clinical backgrounds of the patients
re shown in Table 3. Patients were monitored bimonthly
ith serial determinations of serum ALT, and serum
CV–RNA levels were determined by a branched-chain
NA assay (Lau et al., 1993) (Quantiplex HCV-RNA, Chi-
on, Emeryville, CA). Samples were stored at 270°C until
se. Liver biopsy was performed in patients with a his-
ory of abnormal ALT values, and all had chronic active
epatitis. No significant changes in serum HCV–RNA
evels were observed between the two sampling points
n each patient. Written informed consent was obtained
rom all patients before liver biopsy.
The patients were divided into two groups according
o their clinical courses: four patients with persistently
ormal ALT values (low-ALT group, Patients 1–4) and six
of the Patients
Abnormal ATL groups
Flare-up group High ALT group
Patient 5 Patient 6 Patient 7 Patient 8 Patient 9 Patient 10
57 55 42 55 60 65
M F F M M F
400 675 886 1114 1012 386
35 27 13 102 197 127
147 218 106 — — —
16.6 13.8 8.9 7.7 12.3 18.6
14 15 24 15 10 7.6
15 15 20 12 12 9.0
2 1 3 2 3 2
3 3 3 3 3 3
Desmet et al. (1994).ABLE 3
unds
ent 4
8
F
1
5
6.6
0
8.6
A
A
.
ribed inith elevated ALT values in some points during obser-
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251HCV FULL-LENGTH SEQUENCES AND HEPATITIS ACTIVITYation (abnormal ALT group, Patients 5–10). The abnor-
al ALT group was divided further into two subgroups
ccording to the pattern of ALT elevation; three showed
lare-up of ALT from the normal range to .100 IU/l during
bservation without any medication known to affect ALT
alues (flare-up group, Patients 5–7), and three showed
ersistently high-ALT values (.100 IU/l) (high-ALT group,
atients 8–10). ALT values during the observation period
n representative cases are shown in Fig. 2.
NA extraction
Serum RNA was extracted by a modified acid-gua-
idium-phenol-chloroform method. Briefly, 150 ml of se-
um were mixed with 700 ml of ISOGEN (Wako Pure
hemical Industries, Osaka, Japan), and an aqueous
hase was extracted once with 140 ml of chloroform.
NA was isopropanol-precipitated with 20 mg of glyco-
en (Boehringer Manheim, Manheim, Germany) as a
arrier. Obtained RNA was washed once with ethanol
nd finally dissolved in 10 ml of distilled water and stored
t 270°C until use.
DNA synthesis
Five microliters of the reverse transcription mixture
ere adjusted to contain 1 ml of the RNA solution, 50 U
f Moloney murine leukemia virus reverse transcriptase
MMLV-RT, GIBCO BRL) with an accompanied buffer ac-
ording to the manufacturer’s instructions, 10 units of
Nase inhibitor (Promega Corp., Madison, WI), 50 pg of
andom hexamers (Takara, Kyoto, Japan). The mixture
as incubated at 37°C for 40 min.
CR
The full-length HCV genome except the polyA stretch
as amplified with 21 partially overlapping primer sets
y nested PCR. A hot-start PCR technique with wax
Ampliwax PCR Gem 50, Takara, Kyoto, Japan) was used
FIG. 2. Clinical courses of representative cases in the low-ALT group
oints of the sera.n this study. In the lower solution, 1.5 mM MgCl2, 400 nM af each PCR primer (outer primer), and 200 mM each
-nucleoside triphosphate (dNTP) were included. In the
pper solution, 1 ml of the cDNA solution was made up
o 50 ml of a PCR mixture containing 10 mM of Tris–HCl
pH 8.3), 0.01% gelatin, and 0.5 units of Taq polymerase
AmpliTaq, Promega Corp., Madison, WI) were included.
CR schedules were as follows: for the first-round PCR,
fter denaturing at 94°C for 30 s, 50 cycles of denaturing
t 94°C for 15 s, annealing at 52°C for 15 s, and poly-
erization at 72°C for 30 s and for the second-round
CR, after denaturing at 94°C for 30 s, 40 cycles of
enaturing at 94°C for 15 s, annealing at 55°C for 15 s,
nd polymerization at 72°C for 30 s.
The primers for the whole HCV genome were essen-
ially same as previously reported (Enomoto et al., 1995).
s previously reported (Enomoto et al., 1995), a M13
orward primer and a M13 reverse primer were attached
o the 59 terminal of the sense and antisense second-
ound PCR primers, respectively, to facilitate direct se-
uencing by an automated DNA sequencer (model 373S,
pplied Biosystems Japan). For the determination of the
ecently identified the X-tail region (Tanaka et al., 1995),
he primers with nucleotide sequences shown in the
riginal report were utilized.
equence determination
Each PCR product was purified and residual primers
ere removed with a column (Suprec 02, Takara, Kyoto,
apan) according to the manufacturer’s instructions.
hereafter both strands of the PCR products were cycle-
equenced with the PRISM dye termination kit
CN402069, Applied Biosystems, Japan), according to the
anufacturer’s instructions. The sequencing primers
ere the M13 forward primer for the sense strand and
he M13 reverse primer for the antisense strand. The
roducts were purified with a column (Quickspin column,
oehringer Manheim, Indianapolis, IN) and sequenced
flare-up group (B1), and the high-ALT group (B2). Arrows are sampling(A), theutomatically as mentioned above. Nucleotide and pre-
d
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252 NAGAYAMA ET AL.icted amino acid sequences were compared with the
equence of HCV-J (Kato et al., 1990) as a reference.
tatistical analyses
Determined nucleotide and amino acid sequences
ere compared longitudinally in each patient. Mutation
ates (1023 changes/site/year) of both nucleotides and
mino acids were calculated for every sampling intervals
n the three groups. Mutation rates were calculated in
very fragment of the HCV genome [i.e., 59 noncoding
egion (59NCR), core (C), envelope (E)1, HVR-1, HVR-2, E2,
S2, NS3, NS4A, NS4B, NS5A, NS5B, 39 NCR, X-tail].
oth nucleotide and amino acid mutation rates were
ompared among the three groups by Kruskall–Wallis
est (Statview-J Ver. 4.5, Hulinks Inc., Tokyo), and those
etween two groups by Mann–Whitney’s U test. Bonfer-
oni’s correction was used as a post hoc test of Kruskall–
allis test. All tests of significance were two-tailed, with
values of ,0.05 considered to indicate statistical sig-
ificance.
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